HR 1352
118th Congress
House
Health
Congressional oversight
Government studies and investigations
Health care costs and insurance
Medicare
Prescription drugs
Increasing Access to Biosimilars Act of 2023
Introduced: March 3, 2023
Introduced by:
Hudson, Richard
Republican
· North Carolina
See on congress.gov
Everywhere this bill has been
9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Dec 6, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
Dec 6, 2023
Committee Consideration and Mark-up Session Held
Dec 5, 2023
Committee Consideration and Mark-up Session Held
Nov 15, 2023
Forwarded by Subcommittee to Full Committee by Voice Vote.
Nov 15, 2023
Subcommittee Consideration and Mark-up Session Held
Mar 10, 2023
Referred to the Subcommittee on Health.
Mar 3, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 3, 2023
Introduced in House
Plain-English summary
Increasing Access to Biosimilars Act of 2023
This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
4